Vanda Pharmaceuticals (VNDA) Misses Q1 EPS by 12c

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.07), $0.12 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $47.5 million versus the consensus estimate of $48.5 million.

2024 Financial Guidance

Given continuing uncertainties surrounding the U.S. market for HETLIOZ® for the treatment of Non-24 as a result of continued generic competition in the U.S. and the upcoming commercial launches for Fanapt® in acute bipolar I disorder and PONVORY® in multiple sclerosis, Vanda is unable to provide 2024 financial guidance at this time.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• CBRE Global Real Estate Income Fund adjusts September distribution after split
• UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth